Spring School 2019

133 days

8 hours

25 mins

Our Partners

We are very grateful for support from our partners, please click on any logos below to head to their website.

If you would like to see your logo here, head over to our Sponsorship Guide page to find out how we can work together!

Diamond

Merck

As part of Merck KGaA, Darmstadt, Germany, BioReliance® Services is a key component of the life science services portfolio and the leading provider of contract services in the biopharmaceutical industry. BioReliance’s comprehensive and integrated services support every phase of the testing, development and manufacturing process. With locations worldwide, BioReliance offers more than 1,000 tests and complementary services related to biologics safety testing and specialized toxicology. Our clients include the world’s top producers of traditional pharmaceuticals, medical devices and chemicals, as well as biopharmaceuticals

Oxford Biomedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica has world class facilities and capabilities to support pre-clinical, research and bioprocessing development through to GMP production and supply of commercial and clinical trial materials. The production activities are focused on the manufacture of lentiviral vectors from human cell lines in large scale serum free suspension cultures. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

Platinum

Bluebird Bio

Bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted.

REGENX BIOSCIENCE

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. REGENXBIO is currently developing four product candidates, including RGX-314 for the treatment of wet age-related macular degeneration (wet AMD), RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH), RGX-111 for the treatment of mucopolysaccharidosis type I (MPS I) and RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II).

Lonza

Lonza offers world-class technology platforms in the areas of GMP cell culture and viral-based therapeutic manufacturing, custom bio-therapeutic culture media, a large selection of primary and stem cells and a full line of custom bioassays. Our extensive experience in cell therapy process optimisation and scale-up innovation helps clients to safely and effectively advance their products through all phases of the commercial pipeline and maximise their return on investment. Our new viral-based therapeutics group provides viral vaccine manufacturing as well as viral vector mediated gene therapies. Our staff can design, develop and implement a manufacturing process that meets your autologous or allogeneic therapeutic applications.

MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com.

Intellia

Intellia Therapeutics is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech

Adverum

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Spark

Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. Spark Therapeutics has ongoing clinical trials investigating gene therapies in hemophilia A and B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2 clinical trial as a potential one-time therapy for hemophilia A. The company retains full global commercialization rights to the SPK-FVIII program. SPK-9001, which has received both breakthrough therapy and orphan product designations by FDA, and access to the PRIority MEdicines (PRIME) Program by EMA, is in a Phase 1/2 clinical trial for hemophilia B and is being developed in collaboration with Pfizer. Our most advanced investigational candidate, with proposed trade name LUXTURNA™ (voretigene neparvovec), is currently under Priority Review with FDA for the treatment of biallelic RPE65-mediated IRD and has been designated as a drug for a rare pediatric disease. The MAA for LUXTURNA has been submitted to EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. LUXTURNA has received breakthrough therapy and orphan product designations from FDA and orphan product designations from EMA. The pipeline also includes SPK-7001 in an ongoing Phase 1/2 clinical trial for choroideremia. 

Rocket

Rocket Pharma is a clinical-stage gene therapy company with a multi-platform approach for the treatment of patients with devastating diseases. We leverage LV and AAV transduction strategies towards first-in-class programs. Hall­marks of Rocket’s vision include: 1) a high threshold for the selection of quality programs, 2) leverage of deep industry know-how through a world-class team and manufacturing partnerships and 3) a laser focus on optimizing and innovating gene therapy product parameters through a seasoned scientific approach that de-risks programs as they enter clinical trials.www.rocketpharma.com

Fond National Suisse de la Recherche

The SNSF promotes scientific research in Switzerland. It promotes the international competitiveness and integration of this research as well as its capacity to solve problems. It pays particular attention to the promotion of young researchers.

Sarepta

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates and is proud to support the 2018 AANEM Annual Meeting. For more information about Sarepta.

HipSci

  • Magnitude – HipSci is systematically generating iPSCs from hundreds of donors using a standardised experimental pipeline.
  • Cell line availability – HipSci’s cell lines are produced as a global iPSC resource. The cell lines are readily available from two cell banks (ECACC and EBiSC), for use by the wider research community.
  • Cohorts – HipSci’s reference panel comprises hundreds of cell lines from phenotypically healthy donors, plus several cohorts of donors with inherited genetic diseases.
  • The data – Each line generated is extensively characterised. Assays include genotyping by array, expression array, methylation array, RNA-seq, Exome-seq, proteomics mass spectrometry, and high content cellular phenotyping.

 

Gold

Genethon

Genethon, located in Evry, France, is a non-profit R&D organization dedicated to the design and development of gene therapy treatments for rare genetic diseases from research to clinical validation. It was created by the AFM-Telethon (French Muscular Dystrophy Association) which is its main funding source. Genethon has multiple ongoing programs at clinical, preclinical and research stage for neuromuscular, blood, immune system, and liver diseases. Several of these programs are pursued by Genethon as sponsor, others have been licensed to leading biotech and pharma players in the gene therapy arena such as Audentes, Avexis/Novartis, Gensight Biologics, Orchard Therapeutics, Spark. Genethon was awarded the “Prix Galien France” in 2012.

Human Gene Therapy

Human Gene Therapy is the premier peer-reviewed journal in the field and includes HGT Methods and HGT Clinical Development, providing 22 issues of com­prehensive, end-to-end coverage that is driving today’s explosion of gene therapy advances. Human Gene Therapy serves as the Official Journal of ESGCT. Come visit us at booth 31 to pick up your copy of the special issue dedicated to stem cell gene therapy, and meet Graham Parker, PhD, the Editor-in-Chief of Stem Cells and Development, a premier source of clinical, basic, and translational research on stem cells of all tissue types and their potential therapeutic applications. Stem Cells and Development is an Official Journal of the British Society for Gene and Cell Therapy. Mary Ann Liebert, Inc. publishers is pleased to announce the 2018 launch of The CRISPR Journal, stop by booth 31 or visit www.liebertpub.com/CRISPR for information.

Editas

Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com

Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager’s pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson’s disease, a monogenic form of ALS called SOD1, Huntington’s disease, Friedreich’s ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, AbbVie, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visitwww.voyagertherapeutics.com. 

Molmed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour therapeutics in clinical and preclinical development: Zalmoxis® (TK), a cell-based therapy; NGR-hTNF, a novel therapeutic agent for solid tumours; CAR-CD44v6, an immuno-gene therapy project; MolMed also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trials activities. MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana

Brammer Bio

Brammer Bio is a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies.  Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts.  Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health.  The Brammer team consists of extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients. We are Helping to Cure.®

Maxcyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. The company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

Audentes

Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  Audentes is currently developing four product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

KCT

KCT is newly formed research center in Kuopio, Finland. We provide high quality basic and translational research. Professional team and laboratories with cutting edge devices are providing scientific know-how and modern technologies to develop advanced therapies. We undertake science in collaboration with academic groups all over the world. Link to FinVector's GMP manufacturing, quality and regulatory teams ensures product path from research to patients.
 

Gene Therapy Centre Austria

Available Gene therapy relevant development and manufacturing capabilities and capacities can hardly support the strong growth of gene therapy product development activities across the globe. Long process development times and low yield manufacturing processes slow down product development and add significant costs and risks to the development and licensure of gene therapy products.
The Gene Therapy Center Austria (GTCA) covers all steps from vector to GMP production (200L, 500L, and 1000L) until early stage commercial including a broad range of AAV specific analytical methods.
GTCA’s one-stop-shop concept is based on Shire’s proprietary AAV technology platform. The GTCA has successfully demonstrated lot-to-lot consistency and scalability across multiple programs.
Our partners benefit from our 30+ year experience in development, approval and global supply of complex biologics which reduces product development risks for our development partners and for our CMO clients.
 

Synthego

Synthego is a leading provider of genome engineering solutions. The company’s product portfolio includes software and synthetic RNA kits designed for CRISPR genome editing and research. With next-generation informatics and machine learning, Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
 

Silver

uniQure

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients treat patients with CNS, liver/metabolic and cardiovascular diseases.  We are advancing a focused pipeline of innovative gene therapies and have entered late-stage clinical development in our lead indication, hemophilia B, and have established preclinical proof-of-concept in Huntington’s disease.  www.uniqure.com

Sangamo

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, lysosomal storage disorders MPS I and MPS II, and beta thalassemia. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A and gene regulation programs for C9ORF72-linked amyotrophic lateral sclerosis and frontotemporal lobar degeneration; with Kite, a Gilead Company, for next-generation autologous and allogeneic engineered cell therapies for the treatment of cancer; with Bioverativ, a Sanofi Company, for hemoglobinopathies, including beta thalassemia and sickle cell disease; and with Shire International GmbH to develop therapeutics for Huntington's disease. For more information about Sangamo, visit Sangamo's website at www.sangamo.com.
 

AFM

AFM (French Muscular Dystrophy Association) has a single objective: to defeat neuromuscular diseases, which are devastating muscle-wasting diseases. Created in 1958 by a group of patients and their families, and recognised as being of public utility in 1976, it has set itself two missions: curing neuromuscular diseases and reducing the disabilities they cause.

www.afm-france.org

Orchard therapeutics

Orchard Therapeutics is a fully integrated commercial-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis, the first autologous ex vivo gene therapy approved by the EMA for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for primary immune deficiencies, inherited metabolic disorders and blood disorders include three advanced registrational studies for ADA-SCID, metachromatic leukodystrophy (MLD) and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and beta-thalassemia, as well as an extensive preclinical pipeline.
Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.

BioNTech

BioNTech Innovative Manufacturing Services – EXPERTS IN CELL AND GENE THERAPY MANUFACTURING BioNTech Innovative Manufacturing Services (IMFS) is a German Contract Development and Manufacturing Organisation specialized in the industrialization of cell and gene therapy products (viral vectors, cells and ivt mRNA). Based on extensive expertise in scientific, technical and regulatory prerequisites, we develop and manufacture your products in a safe and cost-efficient way in our state-of-the-art GMP facility. We offer a complete service spectrum from process development through clinical trial to in-market supply. All services are fully integrated and supervised by our QA department ensuring efficient and compliant manufacturing in our state-of-the-art GMP facility.

Abeona

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB- 101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV- FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing its proprietary vector platform, AIM™, for next generation product candidates.

Paragon

Paragon Bioservices is an award-winning Contract Development & Manufacturing Organization (CDMO). Our aim is to build strong client partnerships focusing on transformative technologies, including oncology, immunotherapies (CAR-T cell therapies and oncolytic viruses), new generation vaccines (VLPs) and gene therapies (AAV). Paragon’s cGMP facilities include microbial and mammalian suites, aseptic fil-finish and full-segregated virus facilities.
Responsibility to our clients, a passion for science and our collective need to contribute to better public heath—is what keeps us motivated and excited about the work that we perform. We are driven by our commitment to provide exceptional quality scientific performance and customer service.
With over 25 years in the business, Paragon’s scientists, engineers, quality systems personnel and project managers have many years of experience working with biologics—from research and process development services to GMP manufacturing for clinical trials and eventual commercial launch.
 

Delphi Genetics

Delphi Genetics, located in Belgium, is a biotechnology company specialized in genetic engineering with a deep expertise in plasmid DNA and its applications. Certified GMP we provide technological and flexible biomanufacturing solutions.

Delphi Genetics is involved in several DNA vaccines and gene therapy programs, including the development of CAR-T and collaborates on projects at all stages of development, from R & D to clinical phases. Our complete, GMP-compliant, flexible and single-use process for plasmid DNA manufacturing allows us to provide R&D, High Quality and GMP grade plasmid DNA from a few mg up to several grams in our dedicated facility. 

To support this manufacturing activity, Delphi Genetics also offers a proprietary "antibiotic-free" technology, STABY®. The STABY® technology is implementable in all plasmid DNA and provide a better plasmid stabilization, a production yield increase and a safer way to manufacture plasmid DNA without antibiotic resistance gene following regulatory agencies recommendations.
 

Novasep

Novasep is a CDMO specialized in viruses & viral vectors production for tox, clinical and commercial phases. Novasep offers global and integrated services from process development to commercial manufacturing. For more than 15 years, we have acquired experience in manufacturing viral vectors (lentivirus, AAV, ADV…) for gene therapy and vaccination. Our investment in new commercial assets, addressing both drug substance and drug product manufacturing processes, can help to contribute to your project’s success. Come and meet us at booth 33. 

Selecta Biosciences, Inc

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by mitigating unwanted immune responses.

Yposkesi

Yposkesi is the largest European CDMO for gene therapy vector manufacturing. Created in November 2016 in Corbeil Essonnes (France) as a spin off from the world-class gene therapy pioneer Genethon, Yposkesi provides a full-service offer covering BioProcess development (USP & DSP), from small/pilot to large production scale,analytical development, GMP manufacturing of clinical lots of lentiviral vectors and regulatory support.
Its current facility consists in a 50,000 sq ft building, operating 4 manufacturing suites for bulk drug substance, and 2 Fill & Finish suites.  This capacity will be expanded in 2021 with a large scale facility (50,000 sq ft) equipped with 2,000L bioreactors, designed for commercial production and compliant to EMA and FDA.  Capitalizing on more than 25 years of expertise, Yposkesi significantly invests in innovation in bioprocessing to cost-effectively deliver on high quality projects.
 

Nature TC

Nature Technology Corporation (NTC) partners with biopharmaceutical and drug development companies to produce safe and effective non-viral vectors incorporating the best-in-class minimal NanoplasmidTM vector backbone. NanoplasmidTM vectors comprise a regulatory compliant antibiotic free selection marker (RNA-OUT) combined with a high-manufacturing-yield, host-restricted mini-origin of replication to deliver superior expression level and duration, and reduced transfection associated toxicity. NanoplasmidTM vectors are ideal for gene and stem cell therapies, and as helper and packaging vectors for viral vector manufacture.  NTC provides outsourcing for custom vector design and synthesis, and plasmid manufacturing, using its leading HyperGROTM process, resulting in rapid development of gene and stem cell therapeutics and DNA vaccines
 

Bronze

TiGenix

TiGenix is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. TiGenix´ lead product, Alofisel (darvadstrocel), previously Cx601, received European Commission (EC) approval for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has recently been acquired by Takeda, a global pharmaceutical company active in gastroenterology.

generationbio

Generation Bio aims to do what no other gene therapy platform has yet accomplished: to deliver titratable, re-dosable genetic medicines with drug-like properties to patients with a wide range of genetic diseases.

Axon Mechem

Axon Medchem is a trusted supplier of high-value life science products, providing Axon Ligands™ as world wide recognized drug reference standards for pharmacological research. With more than 2000 excellent quality small molecule inhibitors and modulators targeting more than 850 biological targets, we aim to facilitate your scientific research and development. 

Axon Medchem is also a leading European CRO in medicinal chemistry, specialized in contract research and high-quality synthesis of bio-active and/or drug-like molecules. We have the proven record in developing novel drug candidates and achieving excellence for a decade by providing our dedicated chemistry services for companies and research institutes around the world.

 

Cell Press

Cell Press is a leading publisher of biomedical and physical science research, offering high-quality, cutting-edge research and resources. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research. We are also proud to publish Stem Cell Reports, the official journal of the ISSCR, and the Molecular Therapy family of journals, the portfolio of gene and cell therapy research journals for the ASGCT.

Anemocyte

Anemocyte is a Biotech Manufacturing Organization (BMO): a biotech company that addresses CGT needs pro-actively offering one stop shop solutions and fostering exciting innovations active in the field of Cell and Gene Therapies (CGTs).  
Our experience and know -how come from far:
-        14 years of GMP manufacturing of CGTs and biological drugs;
-        61 years of Contract Manufacturing within our Group (Holding F.I.S.)
Our business includes:
-        Process development and GMP Manufacturing (Somatic Cells, Non-Viral Modified Cells and Extracellular vesicles)
-        Plasmid for Viral Vector Manufacturing
-        Project 2020: up to commercial manufacturing capabilities (Including use of Viral Vectors for CGTs)